![Electroducer announces major medical advance in treatment of heart valve disease; raises €3 million to market its device in Europe and US – commencing in 2022](https://ala.associates/wp-content/uploads/2021/06/Electroducer-clinical-study-Sleeve-4-1080x675.jpg)
![Electroducer announces major medical advance in treatment of heart valve disease; raises €3 million to market its device in Europe and US – commencing in 2022](https://ala.associates/wp-content/uploads/2021/06/Electroducer-clinical-study-Sleeve-4-1080x675.jpg)
![Hephaï files software patent for its digital education platform designed to improve patient inhaler use](https://ala.associates/wp-content/uploads/2021/06/Illustration-de-lutilisation-dun-inhalateur-avec-analyse-des-mouvements-par-la-plateforme-Hephai-1080x675.jpg)
Hephaï files software patent for its digital education platform designed to improve patient inhaler use
![CarThera’s SonoCloud technology enhances the efficacy of immunotherapies for the treatment of brain tumors](https://ala.associates/wp-content/uploads/2021/06/SonoCloud-9-Fond-Bleu-resized.png)
CarThera’s SonoCloud technology enhances the efficacy of immunotherapies for the treatment of brain tumors
![Robocath successfully completes first robotic coronary angioplasties in Belgium](https://ala.associates/wp-content/uploads/2021/05/Pr-S-Verheye-1080x675.jpg)
Robocath successfully completes first robotic coronary angioplasties in Belgium
![Noventure acquires Ulkox® and Oleoabrax®, two medical devices based on patented new wound-healing technology](https://ala.associates/wp-content/uploads/2021/04/Ulkox-Oleoabrax-1080x675.png)
Noventure acquires Ulkox® and Oleoabrax®, two medical devices based on patented new wound-healing technology
![Chiesi and Hephaï join forces to develop AI educational tool to improve inhaler use](https://ala.associates/wp-content/uploads/2021/03/Valery-Trosini-Desert-Hephai.jpeg)
Chiesi and Hephaï join forces to develop AI educational tool to improve inhaler use
![REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease](https://ala.associates/wp-content/uploads/2021/03/Guillaume_Blivet_HD-page-001-1080x675.jpg)
REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease
• Within treated patient group, trends showed improved cognitive and executive functions, improved language comprehension and verbal memory, in comparison to placebo group
• REGEnLIFE’s technology shown to be safe and well-tolerated by patients
• Initial results open up new possibilities for development of brain-gut stimulation device for prevention and treatment of neurodegenerative diseases
![Vygon Group takes part in UICC World Cancer Day 2021](https://ala.associates/wp-content/uploads/2021/02/Image-PNG-5-1080x675.png)
Vygon Group takes part in UICC World Cancer Day 2021
![Endo Tools Therapeutics secures €8 million ($9.5M) in Series D funding led by White Fund](https://ala.associates/wp-content/uploads/2021/01/Endo-Tools-Therapeutics.jpg)
Endo Tools Therapeutics secures €8 million ($9.5M) in Series D funding led by White Fund
![Robocath successfully carries out Europe’s first remote robotic-assisted coronary angioplasty](https://ala.associates/wp-content/uploads/2021/01/Eric-Durand-during-first-remote-PCI-in-Europe-def-1080x675.jpg)